
Markets and investing
Canaccord lifts Amgen price target to $440 after strong quarter and pipeline progress
Canaccord raised its price target on Amgen to $440 from $384 while keeping a Hold rating, citing the company’s third-quarter results, higher 2026 guidance and positive Phase 3 data.


